

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>ABG Management Ltd.</u> (Last) (First) (Middle) <u>#3902, 39/F, E TOWER</u> <u>10 HARCOURT RD CTR</u> (Street) <u>HONG KONG K3</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ProMIS Neurosciences Inc. [PMN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/03/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	02/03/2026		P		700,741	A	\$12.13 ⁽¹⁾	943,090	I	See Footnote ⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Warrants	\$14.4	02/03/2026		P		700,741		⁽⁶⁾	⁽⁶⁾	Common Shares	700,741	⁽¹⁾	700,741	I	See Footnote ⁽³⁾⁽⁴⁾⁽⁵⁾⁽⁷⁾

1. Name and Address of Reporting Person * <u>ABG Management Ltd.</u> (Last) (First) (Middle) <u>#3902, 39/F, E TOWER</u> <u>10 HARCOURT RD CTR</u> (Street) <u>HONG KONG K3</u> (City) (State) (Zip)		

1. Name and Address of Reporting Person *		
Ally Bridge MedAlpha Master Fund L.P.		
(Last)	(First)	(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED, P.O. BOX 309, UGLAND HOUSE,		
(Street)		
GRAND CAYMAN, E9		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *		
Ally Bridge Group (NY) LLC		
(Last)	(First)	(Middle)
430 PARK AVENUE, 12TH FLOOR		
(Street)		
NEW YORK,	NY	10022
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *		
Yu Fan		
(Last)	(First)	(Middle)
#3902, 39/F, E TOWER, 10 HARCOURT RD CTR		
(Street)		
HONG KONG	K3	
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *		
Alex Slanix Paul		
(Last)	(First)	(Middle)
C/O PROMIS NEUROSCIENCES INC. SUITE 200, 1920 YONGE STREET		
(Street)		
TORONTO,	A6	M4S 3E2
(City)	(State)	(Zip)

Explanation of Responses:

- The Warrants were purchased together with the Common Shares reported herein for an aggregate purchase price of \$12.13 per Common Share.
- The Common Shares reported herein include: (i) 407,230 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares held of record by ABG V-SIV X Limited.
- Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P.
- Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited.
- Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited.
- The warrants to purchase Common Shares (the "Warrants") are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event or (ii) February 3, 2031. For purposes of the foregoing, the "Milestone Event" means the public announcement via press release or the filing of a Current Report on Form 8-K by the Issuer of topline data from the cohorts treated with single ascending doses of PMN310.
- The Warrants reported herein include: (i) Warrants to purchase 164,881 Common Shares held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) Warrants to purchase 329,760 Common Shares held of record by ABG V-SIV IX Limited and (iii) Warrants to purchase 206,100 Common Shares held of record by ABG V-SIV X Limited.

Remarks:

Each of ABG Global Life Science Capital Partners V GP Limited, ABG Global Life Science Capital Partners V GP, L.P., Ally Bridge Group Global Life Science Capital Partners V, L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited will file a Form 3 in connection with the transactions reported herein and thereafter are expected to file Forms 4 jointly with the reporting persons.

ABG Management Ltd., By: /s/
Fan Yu, Director

02/05/2026

<u>Ally Bridge MedAlpha Master</u>	
<u>Fund L.P., By: Ally Bridge Group</u>	
<u>(NY) LLC, its manager, By: ABG</u>	<u>02/05/2026</u>
<u>Management Ltd., its managing</u>	
<u>member, By: /s/ Fan Yu, Director</u>	
<u>Ally Bridge Group (NY) LLC, By:</u>	
<u>ABG Management Ltd., its</u>	<u>02/05/2026</u>
<u>managing member, By: /s/ Fan</u>	
<u>Yu, Director</u>	
<u>/s/ Fan Yu</u>	<u>02/05/2026</u>
<u>/s/ Michael Bendetson, Attorney-</u>	<u>02/05/2026</u>
<u>in-Fact for Slanix Alex</u>	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.